GlassScriptPhysician profile
Lilit Pilossyan
NPI 1356753602
$7,128.15
in general payments reported to CMS, 2019-2025
28 companies · $1,152 in 2025
The $1,152 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $245 · 2021: $618 · 2022: $2,119 · 2023: $1,434 · 2024: $1,560 · 2025: $1,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,145 · Education: $0.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,145.34 |
| Education | $0.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,504.72 | 2019-2025 | Prolia, Krystexxa, Evenity |
| Regeneron Healthcare Solutions, INC. | $1,298.97 | 2022-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $745.10 | 2022-2025 | |
| Abbvie INC. | $732.17 | 2021-2025 | |
| Glaxosmithkline, LLC. | $340.95 | 2021-2025 | Benlysta, Trelegy Ellipta, Arexvy |
| Janssen Biotech, INC. | $321.93 | 2022-2025 | Tremfya |
| Radius Health, INC. | $298.88 | 2022-2024 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $272.55 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $234.18 | 2021-2024 | Linzess |
| Aurinia Pharma U.S., INC. | $217.48 | 2021-2024 | Lupkynis |
| Lilly USA, LLC | $213.99 | 2021-2024 | Taltz, Zepbound, Mounjaro |
| Novo Nordisk INC | $195.67 | 2022-2024 | Ozempic, Rybelsus |
| Horizon Therapeutics Plc | $163.57 | 2021-2023 | Krystexxa |
| Ani Pharmaceuticals, INC. | $93.31 | 2024-2025 | Purified Cortrophin Gel |
| Kiniksa Pharmaceuticals International, Plc | $61.96 | 2024 | Arcalyst |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $56.65 | 2021-2022 | |
| Corcept Therapeutics | $54.51 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $42.65 | 2022-2024 | Nuedexta |
| Ucb, INC. | $38.92 | 2025 | Bimzelx |
| Janssen Scientific Affairs, LLC | $34.14 | 2022 | |
| Dexcom, INC. | $31.07 | 2024 | Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $30.05 | 2025 | Zenpep |
| Almatica Pharma LLC | $28.97 | 2024 | Loreev Xr |
| Celltrion USA INC. | $28.53 | 2025 | Vegzelma |
| Fidia Pharma USA INC. | $25.19 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $22.95 | 2023 | Arcalyst |
| Biogen, INC. | $19.55 | 2021 | |
| Mannkind Corporation | $19.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lilit Pilossyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.